A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam Administered as a Two-drug Cocktail in Patients With ALK-positive Advanced Tumors Including Non-small Cell Lung Cancer (NSCLC)
Phase of Trial: Phase I
Latest Information Update: 01 Jun 2017
At a glance
- Drugs Ceritinib (Primary) ; Midazolam; Warfarin
- Indications Non-small cell lung cancer
- Focus Pharmacokinetics
- Sponsors Novartis
- 24 Feb 2017 Planned End Date changed from 1 Feb 2017 to 22 Sep 2017.
- 24 Feb 2017 Planned primary completion date changed from 1 Feb 2017 to 22 Sep 2017.
- 09 Oct 2016 Planned End Date changed from 1 Dec 2016 to 1 Feb 2017.